Capital Research Global Investors Portfolio holdings
Capital Research Global Investors (CRGI), a division of Capital Group established in 1931 and headquartered in Los Angeles, California, is a powerhouse in active investment management, overseeing hundreds of billions in assets with a focus on global equity portfolios. Known for its long-term, research-intensive approach, CRGI employs a unique multiple-portfolio-manager system to diversify risk and enhance returns, serving institutional clients, financial advisors, and individual investors through vehicles like the American Funds mutual fund family. The firm’s investment philosophy emphasizes fundamental analysis and a deep understanding of companies worldwide, aiming to identify growth opportunities over extended horizons. As part of Capital Group’s broader mission, CRGI has built a reputation for delivering consistent, value-driven results in the global investment landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$1.09B |
| 2 |
K
Kellanova
K
|
+$912M |
| 3 |
Teva Pharmaceuticals
TEVA
|
+$774M |
| 4 |
Wells Fargo
WFC
|
+$717M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$604M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$1.36B |
| 2 |
Canadian Natural Resources
CNQ
|
+$927M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$922M |
| 4 |
Crown Castle
CCI
|
+$857M |
| 5 |
McKesson
MCK
|
+$825M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.44% |
| 2 | Technology | 15.01% |
| 3 | Financials | 11.47% |
| 4 | Consumer Discretionary | 10.69% |
| 5 | Communication Services | 10.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
BioMarin Pharmaceuticals
BMRN
$13.7B
| $1.72B | 0.54% |
19,643,433
+390
| +0% | +$34.7K |
|
52
Freeport-McMoran
FCX
$96.8B
| $1.72B | 0.54% |
128,723,380
-20,709,396
| -14% | -$298M |
|
53
Berkshire Hathaway Class B
BRK.B
$1.09T
| $1.69B | 0.53% |
10,160,842
+257,709
| +3% | +$43.1M |
|
54
UBS Group
UBS
$177B
| $1.63B | 0.52% |
102,134,430
-7,118,687
| -7% | -$115M |
|
55
IBM
IBM
$221B
| $1.54B | 0.48% |
9,222,238
-1,040,995
| -10% | -$175M |
|
56
Goldman Sachs
GS
$302B
| $1.53B | 0.48% |
6,652,625
-2,484,665
| -27% | -$600M |
|
57
Costco
COST
$421B
| $1.52B | 0.48% |
9,073,570
-166,601
| -2% | -$27.9M |
|
58
Microsoft
MSFT
$3.66T
| $1.47B | 0.46% |
22,309,799
-189,406
| -0.8% | -$12.1M |
|
59
Gilead Sciences
GILD
$168B
| $1.46B | 0.46% |
21,474,531
-3,298,010
| -13% | -$232M |
|
|
60
Abbott
ABT
$192B
| $1.45B | 0.46% |
32,671,625
+25,159,924
| +335% | +$1.09B |
|
61
Prudential Financial
PRU
$42.3B
| $1.44B | 0.45% |
13,499,840
+1,454,535
| +12% | +$157M |
|
|
VALE.P
62
DELISTED
Vale S A
VALE.P
| $1.41B | 0.44% |
156,976,282
-26,626,151
| -15% | -$250M |
|
63
McDonald's
MCD
$195B
| $1.36B | 0.43% |
10,486,587
-613,416
| -6% | -$77M |
|
64
Western Union
WU
$2.22B
| $1.33B | 0.42% |
65,378,098
+31,185
| +0% | +$637K |
|
|
NLSN
65
DELISTED
Nielsen Holdings plc
NLSN
| $1.3B | 0.41% |
31,359,204
+3,635,373
| +13% | +$156M |
|
66
Qorvo
QRVO
$8.64B
| $1.26B | 0.4% |
18,317,530
| – | – |
|
|
PXD
67
DELISTED
Pioneer Natural Resource Co.
PXD
| $1.25B | 0.39% |
6,687,003
-895,000
| -12% | -$166M |
|
68
Mastercard
MA
$491B
| $1.23B | 0.39% |
10,956,410
+91,159
| +0.8% | +$9.99M |
|
69
Chevron
CVX
$386B
| $1.22B | 0.39% |
11,390,950
-2,812,315
| -20% | -$315M |
|
|
70
McKesson
MCK
$103B
| $1.22B | 0.38% |
8,228,633
-5,630,295
| -41% | -$825M |
|
71
Exelon
EXC
$46.4B
| $1.22B | 0.38% |
47,526,614
-2,609,934
| -5% | -$66.5M |
|
72
Nike
NKE
$60.3B
| $1.22B | 0.38% |
21,860,527
+3,400
| +0% | +$188K |
|
73
Truist Financial
TFC
$64.4B
| $1.2B | 0.38% |
26,899,185
+10,146,305
| +61% | +$474M |
|
74
SLB Ltd
SLB
$78.6B
| $1.13B | 0.36% |
14,466,187
+3,441,288
| +31% | +$281M |
|
|
K
75
DELISTED
Kellanova
K
| $1.13B | 0.36% |
16,545,855
+13,206,274
| +395% | +$912M |
|
Similar funds
Capital Research Global Investors's Q1 2017 Portfolio in Review
As of Q1 2017, Capital Research Global Investors held 457 positions worth $317B, up 2.8% from $308B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Capital Research Global Investors withdrew a net $10.5B in Q1 2017, closing 32 positions and reducing 150 holdings. Its most notable exit was Spectra Energy Corp Wi, an estimated $395M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, down from 17% a quarter earlier, followed by Technology and Financials.
Against the trend, Capital Research Global Investors opened a new position in TransDigm Group worth $346M.
- Capital Research Global Investors's largest Q1 2017 buy was TransDigm Group: 1,570,000 shares worth $346M.
- Capital Research Global Investors added most to Abbott in Q1 2017, an estimated $1.09B increase.
- Capital Research Global Investors's biggest Q1 2017 reduction was Amgen, cutting an estimated $1.36B.
- Capital Research Global Investors fully exited Spectra Energy Corp Wi in Q1 2017, selling an estimated $395M.
- Capital Research Global Investors's ten largest holdings make up 24% of its $317B portfolio in Q1 2017.
- Capital Research Global Investors opened 30 new positions and closed 32 in Q1 2017.
- Capital Research Global Investors's portfolio value rose 2.8% quarter-over-quarter to $317B.
Based on Capital Research Global Investors's 13F filing for Q1 2017, filed 15 May 2017.